Analysis of choroidal thickness changes in exudative age‑related macular degeneration patients treated with aflibercept – preliminary report
More details
Hide details
Klinika Okulistyki CSK MON WIM w Warszawie; kierownik: prof. dr hab. n. med. Marek Rękas
Zakład Informatyki Medycznej i Telemedycyny, Warszawski Uniwersytet Medyczny; kierownik: dr hab. n. med. Wojciech Glinkowski
Publication date: 2017-10-02
LW 2017;95(4):362–366
Aim. To investigate subfoveal choroidal thickness changes in patients with treatment‑naive exudative age‑related macular degeneration in initial phase of aflibercept treatment. Patients and methods. The prospective study included 39 eyes of 39 patients with treatment‑naive exudative AMD, aged 78.1 ±9 years. Loading dose of three intravitreal aflibercept injections at 4 weeks intervals were performed. Measurements were performed at baseline and 7 weeks after last injection. The following parameters were taken into account in statistical analysis: (1) age‑related macular degeneration type; (2) visual acuity changes; (3) disease activity after three loading aflibercept injections. Results. Mean subfoveal choroidal thickness significantly reduced from 197.9 ±113.8 μm to 183.74 ±110.0 μm (p <0.05). Subfoveal choroidal thickness reduction from 217.58 ±111.8 μm to 199.88 ±111.3 (p <0.05) was observed in a group with visual improvement and stabilization. Subfoveal choroidal thickness reduction from 196.95 ±122.9 μm to 178.50 ±112.8 μm (p <0.05) was observed in a group without disease activity. Conclusion. Subfoveal choroidal thickness is reduced in patients with exudative age‑related macular degeneration treated with aflibercept. Subfoveal choroidal thickness reduction is associated with visual improvement or stabilization and reduction of the disease activity.